Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARC R MATRANA

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1598958316
CMS profile
345054
Location
NEW ORLEANS, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$144,481.88

89 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
E.R. Squibb & Sons, L.L.C. $45,632.66 28
AstraZeneca Pharmaceuticals LP $38,090.71 21
Merck Sharp & Dohme Corporation $37,801.75 21
EISAI INC. $11,723.41 11
Janssen Biotech, Inc. $7,783.35 6
Astellas Pharma US Inc $3,450.00 2

Page 2 of 2; records 51–89 of 89 matching records. This page contains 39 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARC R MATRANA

NPI 1598958316 · CMS profile ID 345054

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

NEW ORLEANS, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–89 of 89 matching records. This page contains 39 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1598958316?year=2019&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARC R MATRANA, NPI 1598958316, CMS profile ID 345054. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–89 of 89 matching records. This page contains 39 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1598958316?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). MARC R MATRANA, NPI 1598958316, CMS profile ID 345054. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–89 of 89 matching records. This page contains 39 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1598958316?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
MARC R MATRANA, NPI 1598958316, CMS profile ID 345054, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–89 of 89 matching records. This page contains 39 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1598958316?year=2019&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

89 matching records · $144,481.88 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 89 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–89 of 89.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $100.5908/01/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651379467 CMS
E.R. Squibb & Sons, L.L.C. $705.6508/01/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651379469 CMS
E.R. Squibb & Sons, L.L.C. $12.3808/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651379479 CMS
Merck Sharp & Dohme Corporation $2,750.0007/22/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 708413155 CMS
Merck Sharp & Dohme Corporation $2,750.0007/22/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 708413159 CMS
Merck Sharp & Dohme Corporation $2,750.0007/22/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 708413167 CMS
Merck Sharp & Dohme Corporation $3,500.0007/12/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695647823 CMS
Merck Sharp & Dohme Corporation $2,750.0007/12/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 708413161 CMS
Merck Sharp & Dohme Corporation $86.6107/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695632545 CMS
Merck Sharp & Dohme Corporation $730.0407/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695647820 CMS
Merck Sharp & Dohme Corporation $17.2907/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695640113 CMS
AstraZeneca Pharmaceuticals LP $2,750.0007/02/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685183569 CMS
AstraZeneca Pharmaceuticals LP $2,750.0007/01/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685627381 CMS
EISAI INC. $3,125.0006/25/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697037525 CMS
EISAI INC. $500.0006/25/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697037527 CMS
EISAI INC. $647.3006/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697037529 CMS
EISAI INC. $85.6806/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697037531 CMS
Janssen Biotech, Inc. $500.0006/25/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658582431 CMS
AstraZeneca Pharmaceuticals LP $107.5406/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685996289 CMS
AstraZeneca Pharmaceuticals LP $124.3406/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685700829 CMS
E.R. Squibb & Sons, L.L.C. $4,310.0006/03/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651379387 CMS
E.R. Squibb & Sons, L.L.C. $4,310.0005/22/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651379403 CMS
E.R. Squibb & Sons, L.L.C. $90.0305/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651379389 CMS
E.R. Squibb & Sons, L.L.C. $634.8605/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651379391 CMS
E.R. Squibb & Sons, L.L.C. $682.3105/15/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651379399 CMS
E.R. Squibb & Sons, L.L.C. $97.4805/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651379401 CMS
AstraZeneca Pharmaceuticals LP $2,750.0005/06/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685353183 CMS
E.R. Squibb & Sons, L.L.C. $250.0004/22/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651379513 CMS
AstraZeneca Pharmaceuticals LP $124.3404/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685960597 CMS
E.R. Squibb & Sons, L.L.C. $4,310.0004/17/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651379489 CMS
E.R. Squibb & Sons, L.L.C. $119.3604/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651379491 CMS
AstraZeneca Pharmaceuticals LP $2,050.0004/01/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685245253 CMS
Merck Sharp & Dohme Corporation $2,750.0003/14/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 708413163 CMS
EISAI INC. $122.2503/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697037769 CMS
EISAI INC. $3,125.0003/13/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697037771 CMS
AstraZeneca Pharmaceuticals LP $67.9703/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685724667 CMS
AstraZeneca Pharmaceuticals LP $55.0703/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685835007 CMS
AstraZeneca Pharmaceuticals LP $2,500.0001/14/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685103081 CMS
AstraZeneca Pharmaceuticals LP $5,907.0001/14/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685921611 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $144,481.88 89
PY2020 $91,741.71 72
PY2021 $180,259.14 132
PY2022 $85,133.08 71
PY2023 $94,275.57 76
PY2024 $94,602.95 86
PY2025 $66,471.41 57

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $487,247.24 15
PY2024 Principal investigator $251,085.13 19
PY2023 Principal investigator $641,577.75 54
PY2022 Principal investigator $382,156.45 50
PY2021 Principal investigator $881,375.30 106
PY2020 Principal investigator $603,866.25 189
PY2019 Principal investigator $607,352.60 180

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

15 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $12,916.12 12/31/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma mRCC KEYNOTE No dispute reported 06/30/2026 1232926023
Principal investigator 1 Merck Sharp & Dohme LLC $11,215.36 12/31/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy versus Perioperative Placebo Neoadjuvant Chemotherapy in Cisplatin-Eligible Participants with Muscle-invasive Bladder Cancer KEYNOTE- No dispute reported 06/30/2026 1232927343
Principal investigator 1 Merck Sharp & Dohme LLC $8,433.80 12/31/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 1232931488
Principal investigator 1 Merck Sharp & Dohme LLC $10,951.29 12/31/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Belzutifan MK-6482 and Lenvatinib MK-7902, or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First No dispute reported 06/30/2026 1232934808
Principal investigator 1 Merck Sharp & Dohme LLC $397,600.00 12/09/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
A Phase 1, First-in-Human Study of NTX 1088, a Monoclonal Antibody Targeting the Poliovirus Receptor PVR, as Monotherapy and Combined with Pembrolizumab, in Patients with Advanced Solid Malignancies No dispute reported 06/30/2026 1232936172
Principal investigator 1 Merck Sharp & Dohme LLC $31,110.00 10/06/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Belzutifan MK-6482 and Lenvatinib MK-7902, or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First No dispute reported 06/30/2026 1232934806
Principal investigator 1 Novocure Inc. $2,000.00 08/28/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma No dispute reported 06/30/2026 1250856363
Principal investigator 1 Novocure Inc. $9,000.00 05/15/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma No dispute reported 06/30/2026 1250856361
Principal investigator 1 Novocure Inc. $500.00 05/15/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma No dispute reported 06/30/2026 1250856613
Principal investigator 1 Novocure Inc. $181.44 05/01/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma No dispute reported 06/30/2026 1250856359
Principal investigator 1 Novocure Inc. $181.44 05/01/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma No dispute reported 06/30/2026 1250856435
Principal investigator 1 Novocure Inc. $500.00 01/30/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma No dispute reported 06/30/2026 1250856357
Principal investigator 1 Novocure Inc. $181.44 01/23/2025 Covered Recipient Teaching Hospital
Ochsner Clinic Foundation
EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma No dispute reported 06/30/2026 1250856611
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $338.35 01/21/2025 Non-covered Recipient Entity
Ochsner Clinic
A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus Bempegaldesleukin (NKTR214), Versus Nivolumab Alone Versus Standard of Care in Participants With MuscleInvasive Bladder Cancer (MIBC) Who Are Cisplatin Ineligible No dispute reported 06/30/2026 1235995016
Principal investigator 1 Eli Lilly and Company $2,138.00 01/09/2025 Covered Recipient Teaching Hospital
OCHSNER CLINIC FOUNDATION
A PHASE 1/2 STUDY OF ORAL SELPERCATINIB (LOXO-292) IN PATIENTS WITH ADVANCED SOLID TUMORS, INCLUDING RET FUSION-POSITIVE SOLID TUMORS, MEDULLARY THYROID CANCER, AND OTHER TUMORS WITH RET ACTIVATION (LIBRETTO-001) No dispute reported 06/30/2026 1187874241